Alendronic acid effervescent - EffRx

Drug Profile

Alendronic acid effervescent - EffRx

Alternative Names: Alendronate effervescent; Alendronate sodium; Binosto; Buffered effervescent alendronate; EX-101; Steovess

Latest Information Update: 16 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EffRx
  • Developer Abiogen Pharma; Adcock Ingram Pharmaceuticals; Ahn-Gook Pharmaceutical; Andrus; Ascendancy Healthcare; EffRx; Hikma Pharmaceuticals; Laboratorios Atral; Lacer; Mission Pharmacal
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Osteoporosis

Highest Development Phases

  • Marketed Male osteoporosis; Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 29 May 2017 Alendronic acid effervescent - EffRx is available for licensing as of 29 May 2017. https://www.effrx.com/business-development/
  • 26 May 2017 Launched for Osteoporosis in Egypt, Libya, Tunisia, Algeria, Morocco, Ghana, Kenya, Angola, Mozambique, Sao Tome and Principe, Guinea Bissau, Cape Verde, Zimbabwe, Namibia, Botswana, South Africa, Taiwan, Philippines, Laos, Vietnam, Malaysia, Thailand, Myanmar, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, Kazakhstan, Syria, Iraq, Jordan, Oman, Yemen, Saudi Arabia, United Arab Emirates, Turkey, Moldova, Belarus, Ukraine, Russia, and Indonesia (PO) (EffRx website, May 2017)
  • 26 May 2017 No recent reports on development identified - Registered for Osteoporosis in Bangladesh, New Zealand, Canada, and Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top